Comparison of retroperitoneal and transperitoneal surgical routes in laparoscopic nodal staging for locally advanced cervical cancers (FIGO IB3-IVA). Issue 9 (September 2022)
- Record Type:
- Journal Article
- Title:
- Comparison of retroperitoneal and transperitoneal surgical routes in laparoscopic nodal staging for locally advanced cervical cancers (FIGO IB3-IVA). Issue 9 (September 2022)
- Main Title:
- Comparison of retroperitoneal and transperitoneal surgical routes in laparoscopic nodal staging for locally advanced cervical cancers (FIGO IB3-IVA)
- Authors:
- Pécout, Marie
Phalippou, Jérôme
Azaïs, Henri
Ouldamer, Lobna
Bolze, Pierre Adrien
Ballester, Marcos
Huchon, Cyrille
Mimoun, Camille
Akladios, Cherif
Lecointre, Lise
Raimond, Emilie
Graesslin, Olivier
Carcopino, Xavier
Lavoué, Vincent
Bendifallah, Sofiane
Touboul, Cyril
Dabi, Yohan
Canlorbe, Geoffroy
Koskas, Martin
Chauvet, Pauline
Collinet, Pierre
Kerbage, Yohan - Abstract:
- Abstract: Background: This study compares morbidity and mortality associated with retroperitoneal and transperitoneal para-aortic lymphadenectomy (PAAL) for pretherapeutic nodal staging of locally advanced cervical cancers (FIGO IB3–IVA). Methods: Pre-, per- and postoperative data of patients treated for locally advanced stage cervical cancer between 1999 and 2018 in 12 French referral centers (FRANCOGYN Study Group) were retrospectively collected. Results: The study was conducted using a sample of 448 patients, of whom 223 (49, 8%) underwent retroperitoneal (group 1) and 225 (50, 2%) had transperitoneal PAAL (group 2). No differences were noted concerning clinical and histological characteristics between the two groups. Among these 448 patients, 23 (5, 1%) had an intraoperative complication (9 (2, 0%) in group 1 and 14 (3, 1%) in group 2, p = 0.28) and 47 (10, 5%) had a postoperative complication (22 (4, 9%) in group 1 and 25 (5, 6%) in group 2, p = 0.44), only one of which required revision surgery but the patient died. The length of hospital stay was significantly shorter in group 1 than in group 2 (3.97 versus 4.88 days, p < 0.001). There was no significant difference in mortality between the two groups; 34 of 223 patients in group 1 (15.3%) and 40 of 225 patients in group 2 (15.6%) died (HR = 0.968, 95% CI [0.591–1.585]). There was no significant difference in recurrence-free or overall survival between the two groups. Conclusion: Retroperitoneal PAAL appears as aAbstract: Background: This study compares morbidity and mortality associated with retroperitoneal and transperitoneal para-aortic lymphadenectomy (PAAL) for pretherapeutic nodal staging of locally advanced cervical cancers (FIGO IB3–IVA). Methods: Pre-, per- and postoperative data of patients treated for locally advanced stage cervical cancer between 1999 and 2018 in 12 French referral centers (FRANCOGYN Study Group) were retrospectively collected. Results: The study was conducted using a sample of 448 patients, of whom 223 (49, 8%) underwent retroperitoneal (group 1) and 225 (50, 2%) had transperitoneal PAAL (group 2). No differences were noted concerning clinical and histological characteristics between the two groups. Among these 448 patients, 23 (5, 1%) had an intraoperative complication (9 (2, 0%) in group 1 and 14 (3, 1%) in group 2, p = 0.28) and 47 (10, 5%) had a postoperative complication (22 (4, 9%) in group 1 and 25 (5, 6%) in group 2, p = 0.44), only one of which required revision surgery but the patient died. The length of hospital stay was significantly shorter in group 1 than in group 2 (3.97 versus 4.88 days, p < 0.001). There was no significant difference in mortality between the two groups; 34 of 223 patients in group 1 (15.3%) and 40 of 225 patients in group 2 (15.6%) died (HR = 0.968, 95% CI [0.591–1.585]). There was no significant difference in recurrence-free or overall survival between the two groups. Conclusion: Retroperitoneal PAAL appears as a valuable and safety surgical route for nodal staging in locally advanced cervical cancer compared with standard transperitoneal PAAL. … (more)
- Is Part Of:
- European journal of surgical oncology. Volume 48:Issue 9(2022)
- Journal:
- European journal of surgical oncology
- Issue:
- Volume 48:Issue 9(2022)
- Issue Display:
- Volume 48, Issue 9 (2022)
- Year:
- 2022
- Volume:
- 48
- Issue:
- 9
- Issue Sort Value:
- 2022-0048-0009-0000
- Page Start:
- 2061
- Page End:
- 2067
- Publication Date:
- 2022-09
- Subjects:
- Oncology -- Periodicals
Cancer -- Surgery -- Periodicals
Medical Oncology -- Periodicals
Neoplasms -- surgery -- Periodicals
Cancer -- Chirurgie -- Périodiques
Cancérologie -- Périodiques
Oncologie
Chirurgie (geneeskunde)
Electronic journals
Electronic journals -- Sciences
Electronic journals -- Medicine
Electronic journals
616.994059005 - Journal URLs:
- http://www.ejso.com/ ↗
http://www.sciencedirect.com/science/journal/07487983 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/07487983 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/0720048X ↗
http://firstsearch.oclc.org ↗
http://firstsearch.oclc.org/journal=0748-7983;screen=info;ECOIP ↗
http://www.elsevier.com/journals ↗
http://www.harcourt-international.com/journals ↗
http://www.idealibrary.com/cgi-bin/links/toc/ejso ↗ - DOI:
- 10.1016/j.ejso.2022.05.005 ↗
- Languages:
- English
- ISSNs:
- 0748-7983
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3829.745500
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 23894.xml